<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953576</url>
  </required_header>
  <id_info>
    <org_study_id>08-374</org_study_id>
    <nct_id>NCT00953576</nct_id>
  </id_info>
  <brief_title>Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer</brief_title>
  <acronym>KHLAD</acronym>
  <official_title>A Phase I/II Trial of Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Castration Resistant Prostate Cancer With Pre- and Post-therapy Tumor Biopsies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prostate Cancer Foundation Clinical Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the safety of giving ketoconazole,
      hydrocortisone and dutasteride (KHAD) with lapatinib. Safety is primarily based on dose
      limiting toxicity (DLT) evaluation at various dose levels (DL). The investigators believe
      that there is evidence in castrate resistant prostate cancer (CRPC) that two growth factor
      receptors (EGFR and Her 2/Neu) are increased in prostate cancer (PCa) cells. Both these
      receptors are turned off by the drug lapatinib. By adding lapatinib, the investigators hope
      that signaling from the receptors will be turned off and therefore make the participant's
      cancer more responsive to KHAD treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study builds on investigators' KHAD experience by further targeting pathways that
      may still be enhancing AR activity despite reduced testosterone and DHT. Importantly, studies
      from several groups have shown that EGFR and Her2/Neu activation can enhance AR signaling and
      increase AR transcriptional activity in response to low levels of androgens. Evaluation in
      the clinic and lab has shown that there is increased expression of EGFR or Her2/Neu in CRPC.
      In addition to upregulation in EGFR and Her2/Neu protein expression, signaling through these
      receptors may be enhanced in some tumors by increases in growth factor levels or other
      mechanisms. Based on these results, the investigators suggest that EGFR and Her2/Neu
      contribute to enhancing AR transcriptional activity especially at low androgen levels. If
      this hypothesis is correct, then dual blockade of EGFR and Her2/Neu in CRPC should enhance
      the ability of KHAD to abrogate AR activity. Moreover, as androgens can protect PCa cells
      from cell death in response to EGFR/Her2/Neu/PI3 kinase pathway inhibition, we propose that
      KHAD plus lapatinib may be a particularly active combination therapy for CRPC.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study terminated early due to concerns about drug toxicity.
  </why_stopped>
  <start_date type="Actual">September 29, 2009</start_date>
  <completion_date type="Actual">April 11, 2013</completion_date>
  <primary_completion_date type="Actual">April 11, 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The Phase I dose escalation schedule was to evaluate up to 4 dose levels of lapatinib as well as one step down dose for ketoconazole (-1). This is not a 'parallel assignment' since this dose escalation design proceeds in sequence not in parallel.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lapatinib Maximum Tolerated Dose (MTD) [Phase I]</measure>
    <time_frame>The evaluation for MTD occurred continuously through one cycle of KHLAD treatment (28 days).</time_frame>
    <description>The MTD of lapatinib in combination with KHAD is determined by the number of participants who experience a dose limiting toxicity (DLT) at the various dose levels of lapatinib under evaluation. See subsequent primary outcome measure for the DLT definition. The MTD is defined as the lapatinib dose at which fewer than one-third of patients experience a DLT. If no DLTs are observed, the MTD is not reached and the Recommended Phase II Dose (RP2D) will be based on safety and pharmacokinetic results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lapatinib Dose Limiting Toxicity (DLT) [Phase I]</measure>
    <time_frame>The evaluation for DLT occurred continuously through one cycle of treatment (28 days).</time_frame>
    <description>A DLT is defined as an adverse event (AE) occurring during the first cycle of KHLAD treatment that are determined to related to the Lapatinib or the combination as follows:
Any Grade 3 or greater non-hematological treatment related (possible, probable, or definite attribution) including diarrhea
Grade 4 or greater for hematological toxicities, regardless of attribution.
Grade 3 skin reactions, pulmonary reactions, regardless of attribution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Lapatinib Levels [Phase I]</measure>
    <time_frame>After first 28 days of KHLAD treatment</time_frame>
    <description>Plasma lapatinib levels were measured after day 28 of KHLAD treatment. Participants were instructed to fast prior to samples being taken.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 3-4 Treatment-Related Adverse Events Rate</measure>
    <time_frame>Assessed each cycle throughout treatment. Treatment duration in months was a median (range) of 5.4 months (range 1 day-8.3 months). Thus, AEs were evaluated up to 8.3 months.</time_frame>
    <description>All grade 3-4 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv4 as reported on case report forms were counted to calculate the proportion of participants experiencing at least one treatment-related grade 3 or 4 AE of any type on treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I Dose Level 1 (DL1): KHAD+L (250 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose Level 2 (DL2): KHAD+L (500 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All Phase I Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: according to the established dose escalation schedule
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
    <arm_group_label>All Phase I Participants</arm_group_label>
    <arm_group_label>Phase I Dose Level 1 (DL1): KHAD+L (250 mg)</arm_group_label>
    <arm_group_label>Phase I Dose Level 2 (DL2): KHAD+L (500 mg)</arm_group_label>
    <other_name>Nizoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrocortisone</intervention_name>
    <arm_group_label>All Phase I Participants</arm_group_label>
    <arm_group_label>Phase I Dose Level 1 (DL1): KHAD+L (250 mg)</arm_group_label>
    <arm_group_label>Phase I Dose Level 2 (DL2): KHAD+L (500 mg)</arm_group_label>
    <other_name>Cortef</other_name>
    <other_name>Hydrocortone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dutasteride</intervention_name>
    <arm_group_label>All Phase I Participants</arm_group_label>
    <arm_group_label>Phase I Dose Level 1 (DL1): KHAD+L (250 mg)</arm_group_label>
    <arm_group_label>Phase I Dose Level 2 (DL2): KHAD+L (500 mg)</arm_group_label>
    <other_name>Avodart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib</intervention_name>
    <arm_group_label>All Phase I Participants</arm_group_label>
    <arm_group_label>Phase I Dose Level 1 (DL1): KHAD+L (250 mg)</arm_group_label>
    <arm_group_label>Phase I Dose Level 2 (DL2): KHAD+L (500 mg)</arm_group_label>
    <other_name>lapatinib ditosylate</other_name>
    <other_name>Tyverb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CRPC with metastatic bone disease. At least one site of metastatic
             disease must be amenable to a needle biopsy. Bone sites include lumbar vertebrae,
             pelvic bones and long bones. Excluded sites are thoracic, cervical vertebrae, skull
             and rib lesions

          -  Patients may have had a number of previous hormonal therapies including ketoconazole
             and abiraterone, provided these were discontinued &gt;3 months before starting the trial

          -  Patients may have had any number of previous cytotoxic therapies

          -  Castrate resistant disease as defined by PSA working group. Patients must have a rise
             in PSA on two successive determinations at least one week apart and PSA levels 5ng/ml
             or greater and testosterone levels &lt;50

          -  Adequate renal, hepatic and bone marrow function as outlined in protocol

          -  PTT&lt; 60, INR &lt;1.5NL unless on warfarin therapy

          -  &gt; 6 month life expectancy

          -  At least a 4 week interval from previous treatment other than LHRH analog and
             bisphosphonates. Patients on bicalutamide must have discontinued this medication for
             at least 6 weeks to be eligible

          -  Patients receiving bisphosphonate can be maintained on this therapy

          -  No major surgery or radiation therapy within 4 weeks

          -  No strontium-89 or samarium-153 therapy within 4 weeks

          -  ECG showing normal QT interval

          -  No thromboembolism in past 6 months

          -  Age &gt; 18 years

          -  Investigator must check current patient medications against the list of CYP3A4
             inhibitors and inducers prior to registration

          -  Echocardiogram or MUGA demonstrating ejection fraction within institutional normal
             limits

        Exclusion Criteria:

          -  No previous therapy with lapatinib

          -  No previous therapy with ketoconazole within 3 months of starting trial

          -  The use of complementary therapy directed at prostate cancer treatment excluding the
             following: green tea, commercial multivitamin preparations. Vitamin B complex, C, D, E
             and multivitamins are permitted if these are being taken at less than 3 times the RDA

          -  The concomitant use of drugs known to be narrow therapeutic index CYP3A4 substrates
             are excluded

          -  Drugs that are sensitive to CYP3A4 substrates are excluded

          -  Patients taking drugs that may further prolong QT intervals and present a known risk
             for Torsades de Pointes are excluded.

          -  Patients who have alcohol or drug dependence currently or in the last 6 months are
             excluded from this study

          -  Any other events, other than those defined above, in the opinion of the investigator,
             may make the patient ineligible for this trial

          -  No contraindication to biopsy such as bleeding disorders. Patients on anticoagulants
             such as warfarin must be able to safely stop the drug for a three-day period. Patients
             may not go on heparin during this time

          -  No active malignancy other than skin cancer or superficial bladder cancer

          -  Cardiac disease: congestive heart failure &gt; class II NYHA. Patients must no have
             unstable angina or new onset angina or myocardial infarction within the past 6 months.
             Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. Patients must have
             an ejection fraction within normal limits at the enrolling institution based on an
             echocardiogram

          -  Uncontrolled hypertension defined as sustained BP &gt; 160 and diastolic &gt; 100 despite
             optimal medical management

          -  Known HIV or chronic Hep B or C

          -  Thrombolic or embolic events such as CVA within the last 6 months

          -  Pulmonary hemorrhage or any bleeding event CTCAE Grade 2 or greater within 6 months of
             first dose of study drug of KHAD

          -  Serious non-healing wound, ulcer, or bone fracture

          -  Evidence of history of bleeding diathesis or coagulopathy

          -  Major surgery or significant traumatic injury within 4 weeks of first study drug of
             KHAD
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Bubley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <results_first_submitted>May 21, 2018</results_first_submitted>
  <results_first_submitted_qc>August 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2018</results_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Glenn Bubley, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>castration resistant prostate cancer</keyword>
  <keyword>KHAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants enrolled from September 2009 until December 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I Dose Level 1: KHAD+L (250 mg)</title>
          <description>For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
        </group>
        <group group_id="P2">
          <title>Phase I Dose Level 2: KHAD+L (500 mg)</title>
          <description>For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>DLT Evaluable</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic (PK) Evaluable</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4">One participant enrolled on dose level 1 did not receive full dose ketoconazole and was replaced.</participants>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible after Consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis dataset is comprised of all enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase I Dose Level 1: KHAD+L (250 mg)</title>
          <description>For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
        </group>
        <group group_id="B2">
          <title>Phase I Dose Level 2: KHAD+L (500 mg)</title>
          <description>For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="51" upper_limit="87"/>
                    <measurement group_id="B2" value="67" lower_limit="65" upper_limit="69"/>
                    <measurement group_id="B3" value="67" lower_limit="51" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lapatinib Maximum Tolerated Dose (MTD) [Phase I]</title>
        <description>The MTD of lapatinib in combination with KHAD is determined by the number of participants who experience a dose limiting toxicity (DLT) at the various dose levels of lapatinib under evaluation. See subsequent primary outcome measure for the DLT definition. The MTD is defined as the lapatinib dose at which fewer than one-third of patients experience a DLT. If no DLTs are observed, the MTD is not reached and the Recommended Phase II Dose (RP2D) will be based on safety and pharmacokinetic results.</description>
        <time_frame>The evaluation for MTD occurred continuously through one cycle of KHLAD treatment (28 days).</time_frame>
        <population>The analysis dataset is comprised of all DLT evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>All Phase I Participants KHAD+L</title>
            <description>For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: orally 1x day according to the established dose escalation schedule
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Lapatinib Maximum Tolerated Dose (MTD) [Phase I]</title>
          <description>The MTD of lapatinib in combination with KHAD is determined by the number of participants who experience a dose limiting toxicity (DLT) at the various dose levels of lapatinib under evaluation. See subsequent primary outcome measure for the DLT definition. The MTD is defined as the lapatinib dose at which fewer than one-third of patients experience a DLT. If no DLTs are observed, the MTD is not reached and the Recommended Phase II Dose (RP2D) will be based on safety and pharmacokinetic results.</description>
          <population>The analysis dataset is comprised of all DLT evaluable participants.</population>
          <units>mg 1x daily</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">While 2 DLTs occurred at DL2, the MTD was not established as DL1 because based on PK analysis, the observed level of lapatinib was well above therapeutic levels which raised sufficient concern to terminate the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lapatinib Dose Limiting Toxicity (DLT) [Phase I]</title>
        <description>A DLT is defined as an adverse event (AE) occurring during the first cycle of KHLAD treatment that are determined to related to the Lapatinib or the combination as follows:
Any Grade 3 or greater non-hematological treatment related (possible, probable, or definite attribution) including diarrhea
Grade 4 or greater for hematological toxicities, regardless of attribution.
Grade 3 skin reactions, pulmonary reactions, regardless of attribution.</description>
        <time_frame>The evaluation for DLT occurred continuously through one cycle of treatment (28 days).</time_frame>
        <population>The analysis dataset is comprised of all DLT evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Dose Level 1: KHAD+L (250 mg)</title>
            <description>For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Phase I Dose Level 2: KHAD+L (500 mg)</title>
            <description>For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Lapatinib Dose Limiting Toxicity (DLT) [Phase I]</title>
          <description>A DLT is defined as an adverse event (AE) occurring during the first cycle of KHLAD treatment that are determined to related to the Lapatinib or the combination as follows:
Any Grade 3 or greater non-hematological treatment related (possible, probable, or definite attribution) including diarrhea
Grade 4 or greater for hematological toxicities, regardless of attribution.
Grade 3 skin reactions, pulmonary reactions, regardless of attribution.</description>
          <population>The analysis dataset is comprised of all DLT evaluable participants.</population>
          <units>participants with DLT</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Lapatinib Levels [Phase I]</title>
        <description>Plasma lapatinib levels were measured after day 28 of KHLAD treatment. Participants were instructed to fast prior to samples being taken.</description>
        <time_frame>After first 28 days of KHLAD treatment</time_frame>
        <population>The analysis dataset is comprised of participants who received KHLAD and had an evaluable plasma sample after the first cycle (day 28).</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Dose Level 1: KHAD+L (250 mg)</title>
            <description>For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Phase I Dose Level 2: KHAD+L (500 mg)</title>
            <description>For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Lapatinib Levels [Phase I]</title>
          <description>Plasma lapatinib levels were measured after day 28 of KHLAD treatment. Participants were instructed to fast prior to samples being taken.</description>
          <population>The analysis dataset is comprised of participants who received KHLAD and had an evaluable plasma sample after the first cycle (day 28).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="731" lower_limit="416" upper_limit="1424"/>
                    <measurement group_id="O2" value="1506" lower_limit="680" upper_limit="2186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade 3-4 Treatment-Related Adverse Events Rate</title>
        <description>All grade 3-4 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv4 as reported on case report forms were counted to calculate the proportion of participants experiencing at least one treatment-related grade 3 or 4 AE of any type on treatment.</description>
        <time_frame>Assessed each cycle throughout treatment. Treatment duration in months was a median (range) of 5.4 months (range 1 day-8.3 months). Thus, AEs were evaluated up to 8.3 months.</time_frame>
        <population>The analysis dataset is comprised of all participants who ever started treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Dose Level 1: KHAD+L (250 mg)</title>
            <description>For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.
For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Phase I Dose Level 2: KHAD+L (500 mg)</title>
            <description>For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 3-4 Treatment-Related Adverse Events Rate</title>
          <description>All grade 3-4 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv4 as reported on case report forms were counted to calculate the proportion of participants experiencing at least one treatment-related grade 3 or 4 AE of any type on treatment.</description>
          <population>The analysis dataset is comprised of all participants who ever started treatment.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.451"/>
                    <measurement group_id="O2" value="0.40" lower_limit="0.076" upper_limit="0.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed each cycle throughout treatment. Median (range) treatment duration (months) for dose level 1: 5.5 (1.8-8.3) and dose level 2: 5.4 (0.2-17.9). Thus, AEs were followed up to 17.9 months.</time_frame>
      <desc>The analysis dataset is comprised of all participants who ever started treatment. Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment attribution of possibly, probably or definitely and grade 3 or higher. All remaining events regardless of treatment attribution were classified as Other AEs. No further data is available to specify classification of other beyond the general term.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase I Dose Level 1: KHAD+L (250 mg)</title>
          <description>For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
        </group>
        <group group_id="E2">
          <title>Phase I Dose Level 2: KHAD+L (500 mg)</title>
          <description>For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.
Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day
Participants are treated until unacceptable toxicity, disease progression or withdrawal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac-other</sub_title>
                <description>AE connected with grade 3 or higher EKG changes</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphatics-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Incontinence, anal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lip, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rectum, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Gr0-2 neut, urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut, urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC ungual (nails)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Stoma, GI hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>QTc interval</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back, pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chest wall, pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Extremity-limb, pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Joint, pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nonneuropathic lower extr muscle weak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Renal/GU-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urine color</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicle, pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nose, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early due to concern of exposure levels observed in PK analyses for the drug under investigation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Glenn Bubley, MD</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <email>gbubley@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

